Stamford Health becomes first U.S. hospital to use FUSMobile’s Neurolyser XR for low back pain

Stamford Health has become the first hospital in the United States to install and use FUSMobile’s Neurolyser XR, with the first patient treated Aug. 18 at Tully Health Center in Stamford, Connecticut. The focused-ultrasound system offers a noninvasive option for selected patients with chronic facet-mediated low back pain and marks an early U.S. commercialization milestone after FDA authorization in November 2025.

Why it matters: - Stamford Health’s adoption of Neurolyser XR gives U.S. patients a new noninvasive option for chronic low back pain linked to the facet joints. - The system is designed to reduce the need for needle-based radiofrequency ablation procedures. - The installation also marks a commercial step for focused ultrasound in interventional pain medicine.

What happened: - FUSMobile announced that Stamford Health became the first hospital in the United States to install Neurolyser XR and treat patients with the system. - The first patient was treated on Aug. 18, 2026, by Dr. Ofer Wellisch at Stamford Health’s Tully Health Center in Stamford, Connecticut. - The first procedure took place at Tully Health Center, part of Stamford Health’s outpatient and specialty care network.

The details: - Neurolyser XR uses focused ultrasound guided by X-ray imaging to treat small nerves in the lower back that can drive chronic pain. - The treatment is delivered from outside the body, so physicians do not need to insert needles or probes to reach the targeted nerves. - The system directs ultrasound energy to a precise point, where it heats and destroys the targeted nerve while surrounding tissue receives much lower energy levels. - The device is designed as a noninvasive alternative to conventional needle-based radiofrequency ablation for appropriately selected patients with chronic low back pain related to the facet joints. - FUSMobile says the installation at Stamford Health follows FDA authorization of Neurolyser XR in November 2025. - Neurolyser technology is already being used internationally, with patients treated in multiple countries. - Dr. Wellisch leads Stamford Health’s Division of Pain Medicine and is part of the Hospital for Special Surgery Spine Center with Stamford Health and the Columbia University Vagelos College of Physicians and Surgeons Neuroscience Continuum. - Stamford Health’s Division of Pain Medicine worked with its Department of Research to move the treatment from a research protocol into clinical care. - Stamford Health is a nonprofit independent health care system serving Fairfield County, Connecticut, with more than 4,100 employees, a 305-bed Stamford Hospital, 40 Stamford Health Medical Group offices and a growing number of ambulatory locations. - Stamford Health says it receives support through the Stamford Hospital Foundation to sustain core medical programs, acquire technology and enhance patient care. - More information is available in the company’s announcement.

Between the lines: - The launch suggests focused ultrasound is moving from clinical trial settings into everyday hospital pain care. - Stamford Health’s role as the first U.S. hospital may help speed broader adoption if physicians see the system as effective and easier to deliver than needle-based procedures. - FUSMobile is positioning Neurolyser XR as part of a wider push to expand image-guided focused ultrasound for interventional pain management.

What’s next: - FUSMobile is likely to use the Stamford Health launch as a proof point for broader U.S. hospital adoption. - Stamford Health is expected to continue offering the technology to appropriately selected patients with chronic facet-mediated low back pain. - Additional treatment sites and more patient cases could further test how well the system fits into routine pain medicine practice.

The bottom line: - Stamford Health has become the first U.S. hospital to bring a noninvasive focused-ultrasound treatment for chronic low back pain into clinical use.